Abstract: Objective To analyze the development trends of patents in stroke field in China based on PatSnap patent information, and provide reference for the strategic decision and science and technology innovation of relevant government departments, enterprises and research institutions. Methods Based on the PatSnap patent database, the patent literatures in stroke field applied in Intellectual Property Administration of China from 2000 to 2020 were searched, and the application trends, main patent technologies and development trend, main applicants, important patents, patent licenses and other aspects were analyzed. Results In the past 20 years, the number of patents applied in stroke field in China summed up to 15 160, and the trend continued to grow. The main technologies focused on drugs for treatment of cardiovascular diseases, pharmaceutical preparations containing organic active ingredients, drugs for treatment of neurological diseases. The main applicants were foreign pharmaceutical companies such as Hoffman Laroche Co, Ltd, followed by domestic universities. Patents with the largest scale, the most claims and the highest market value were all applied by foreign subjects. Since 2004, the highest percentage of patent license per year was 3.12%. Conclusions In the field of stroke, foreign patent technologies had a great impact on Chinese technological innovation. The patent quantity and quality of domestic subjects urgently need to be improved. It is suggested that domestic subjects should pay attention to the undeveloped research field. The patent license should be encouraged to promote stroke research development in China. 【Key

Key words: Patent; Stroke; Development Trend; Applicant; PatSnap

摘要：

目的 基于智慧芽（PatSnap）专利信息对我国卒中领域专利发展态势进行分析，为有关政府部门、 医药企业和科研机构的决策规划和科技创新工作提供参考。 

方法 利用PatSnap专利数据库,检索2000-2020年在我国申请的卒中领域专利文献，从申请趋势、 主要技术和发展趋势、主要申请人、重要专利、专利许可等维度进行分析。 

结果 2000-2020年中国卒中领域专利申请累计15 160件，呈持续增长态势。主要专利技术集中于治疗心血管系统疾病的药物、含有机有效成分的医药配制品、治疗神经系统疾病的药物等方面。主要申请人以弗哈夫曼拉罗切有限公司、阿斯特拉曾尼卡有限公司、赛诺菲、辉瑞大药厂、沃泰克斯药物 股份有限公司、艾伯维公司、勃林格殷格翰国际有限公司和詹森药业有限公司等国外医药公司为主， 其次是首都医科大学和中国药科大学等国内高校。规模最大、权利要求最多、市场价值最高的10大专利均为国外主体申请。专利许可从2004年开始，各年许可百分比最高为3.12%。 

结论 在卒中领域，国外专利技术对于我国技术创新的影响较大，国内主体申请专利的数量和质量亟待提高。建议国内主体注重未开发领域的研究，鼓励和促进专利许可，助力我国卒中科研的发展。

关键词: 专利; 卒中; 发展态势; 申请人; 智慧芽